4 clinics shown
Dr. Eyuel Terefe practices general psychiatry in Yuma, providing evaluations and medication management for adults with mental health conditions. The practice is located on East 31st Place and operates under Onvida Health. Specific treatment modalities such as TMS, ketamine, or esketamine are not listed in available information; patients should inquire directly about procedural or specialized depression treatments beyond standard psychiatric care.
Onvida Health Outpatient Behavioral Health provides psychiatric services for adults and adolescents in Yuma, located on East 31st Place near the city's eastern residential areas. The practice focuses on medication management and diagnostic evaluations for mood disorders, anxiety, and other behavioral health conditions. Specific procedural treatments such as TMS or esketamine are not listed in available data; patients requiring those interventions should inquire directly about current offerings or referral options.
Onvida Health Yuma Medical Center operates a hospital facility on South Avenue A in Yuma, providing inpatient and outpatient medical services to the region. The facility's psychiatric and behavioral health offerings are not specified in available listings; patients seeking TMS, esketamine, or ketamine treatments should contact the hospital directly to confirm whether these modalities are available. As a general hospital, the center may provide psychiatric consultation and crisis stabilization services alongside its broader medical care.
The Healing Journey operates a mental health practice in Yuma, located on South Kennedy Lane near the city's medical district. The facility provides outpatient psychiatric services for adults and adolescents, including diagnostic evaluations and ongoing mental health treatment. Specific treatment modalities such as TMS, ketamine, or esketamine are not detailed in available information; prospective patients should inquire directly about specialized interventions for treatment-resistant conditions.
Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.
Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.
Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.
The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.
Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.